September 14, 2018 09:40 AM EDTUpdated September 17, 07:51 AM
News Briefing

Hua Med­i­cine reaps $110.5M, ad­just­ing ex­pec­ta­tions for Hong Kong IPO

Amber Tong

→ Shang­hai-based di­a­betes drug­mak­er Hua Med­i­cine has con­clud­ed its Hong Kong IPO with a $110.5 mil­lion (HK$867 mil­lion) raise by pric­ing at the low …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

A service from the Financial Times